Journal de l'hypertension : accès libre

Investigation of Pentraxin 3 Levels in Hypertensive Patients with Stroke, Retinopathy and Nephropathy

Abstract

Adem Parlak, Umit Aydogan, Serkan Mutlu, Tuncer Cayci, Bayram Koc and Kenan Saglam

Background: In this study, we aimed to determine PTX3 levels in hypertensive patients with nephropathy, retinopathy and stroke.

Methods: This study is considering totally 135 patients including normotensives and newly diagnosed hypertensive and hypertensive with nephropathy, retinopathy and stroke. Blood samples were extracted to perform biochemical tests and PTX3 levels.

Results: It is observed that PTX3 levels in the normotensive patients, isolated hypertensive patients and hypertensive patients have complication resulted with statistically differences (0.19 ± 0.15 ng/Ml, 37.15 ± 8.02 ng/Ml, 451.28 ± 244.39 ng/mL, p<0.00001). This arises from the differences between the PTX3 levels which belong the patient group has complication along with other groups and isolated hypertensive group along with normotensive group by the performed Post Hoc analyze. If the patients have complication are compared with each other, it is observed PTX3 level in the retinopathy group is statistically higher with reference to other groups (In retinopathy, neuropathy and nephropathy groups’ 710.90 ± 254.6 ng/mL, 408.14 ± 65.56 ng/mL, 253.61 ± 62.66 ng/mL, p<0.0001 respectively). It was established PTX3 levels in the complicated hypertensive patients is associated with BMI and LDL/HDL by the performed multivariate regression analysis (For BMI, LDL/HDL is respectively R square=0.085, F=5.84 and p=0.019 versus R square=0.153, F=5.61 and p=0.006).

Conclusion: It is observed in the present study that in hypertensive patients with stroke and retinopathy and nephropathy, and isolated hypertensive, PTX3 levels are elevated. It is also found BMI and LDL/HDL is associated with PTX3 levels.